Morningstar13d
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
"Anti-CD40L modulates T cell function and has the ... PMID: 38354138 2Gelman, M. Endpoints. "Biogen, UCB detail response rates in Phase 3 lupus trial after surprising Success" Nov. 19, 2024 ...
pharmaphorum6d
UCB, Biogen lupus drug scores in phase 3 trial
For Biogen, dapirolizumab pegol is part of a push ... "Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE ...
BioSpace13d
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
“Anti-CD40L modulates T cell function and has the potential to ... PMID: 38354138 2 Gelman, M. Endpoints. “Biogen, UCB detail response rates in Phase 3 lupus trial after surprising Success” Nov. 19, ...
BioSpace1d
Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants
It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...
Yahoo Finance13d
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
The promise of CD40L blockers is to modulate the immune system rather than suppress it. Traditional immunosuppression drugs work for transplant and autoimmune diseases, but they carry a number of ...
Yahoo Finance14d
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients
March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Benzinga.com14d
Decoding Biogen's Options Activity: What's the Big Picture?
Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...
Nasdaq20d
What the Options Market Tells Us About Biogen
High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...